Treatment of benign prostatic hyperplasia with α 1-receptor antagonists. Correct dosage to ensure optimal outcomes;α 1-rezeptorenblockade zur therapie des BPH-syndroms. Richtige dosierung für optimale wirkung

Urologe - Ausgabe A

Volumn 41, Issue 5, 2002, Pages 452-457

  Berges, R R ^a   Michel, M C ^b   Jonas, U ^c  

^a PAN Klinik am Neumarkt   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Alpha receptor antagonists; Benign prostatic hyperplasia (BPH); Medical therapy; Review

Indexed keywords

ALFUZOSIN; ALNA; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARDULAR PP URO; DIBLOCIN PP URO; DOXAZOSIN; FLOTRIN MAX; FLOTRIN PRO; FLOTRIN START; FLOTRIN URO; PLACEBO; TAMSULOSIN; TERAZOSIN; URIDUCT; URION S; UROXATRAL S; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; GERMANY; HUMAN; LOW DRUG DOSE; MALE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; SYMPTOMATOLOGY; URINE FLOW RATE; BLADDER OBSTRUCTION; COMPARATIVE STUDY; DRUG ANTAGONISM; REVIEW; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC, ALPHA-1; TREATMENT OUTCOME; URINARY BLADDER NECK OBSTRUCTION;

EID: 2242431555     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-001-0151-5     Document Type: Article

References (23)

1. Djavan B, Marberger M (1999) A meta-analysis on the efficacy and tolerability of alpha 1adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 1-13
2. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P (1991) Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group Lancet 337: 1457-1461
3. Hansen BJ, Nordling J, Mensink HJ, Walter S, Meyhoff HH (1994) Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group. Scand J Urol Nephrol 157 [Suppl]: 169-176
4. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P (2000) Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol 37: 306-313
5. Buzelin JM, Fonteyne E, Kontturi M, Witjes WP, Khan A (1997) Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol 80: 597-605
6. Buzelin JM, Delauche-Cavallier MC, Roth S, Geffriaud-Ricouard C, Santoni JP (1997) Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br J Urol 79: 898-904
7. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N (1995) Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 154: 105-109
8. Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, Dias N (1995) Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebocontrolled, dose-response multicenter study. J Urol 154: 110-115
9. MacDiarmid SA, Emery RT, Ferguson SF, McGuirt-Franklin R, McIntyre WJ, Johnson DE (1999) A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia. J Urol 162: 1629-1632
10. Gratzke PKirby RS (2000) Doxazosin GITS versus regular doxazosin in benign prostatic hyperplasia. Restoring urine flow and sexual function more easily. MMW Fortschr Med 142: 40
11. Andersen M, Dahlstrand C, Hoye K (2000) Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 38: 400-409
12. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K (2001) A combined analysis of doubleblind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 87: 192-200
13. Abrams P, Speakman M, Stott M, Arkell D, Pocock R (1997) A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 80: 587-596
14. Lepor H (1998) Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 51: 892-900
15. Narayan Ptewari A (1998) A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 160: 1701-1706
16. Di Silverio F (1992) Use of terazosin in the treatment of benign prostatic hyperplasia: experience in Italy. Br J Urol 70 [Suppl 1]: 22-26
17. Di Silverio F, D'Eramo G, Flammia GP, Buscarini M, Frascaro E, Mariani M, Sciarra A (1993) Pharmacological combinations in the treatment of benign prostatic hypertrophy. J Urol 99: 316-320
18. Lepor H, Auerbach S, Puras-Baez A et al. (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148: 1467-1474
19. Brawer MK, Adams G, Epstein H (1993) Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Arch Fam Med 2: 929-935
20. Elhilali MM, Ramsey EW, Barkin J et al. (1996) A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 47: 335-342
21. Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DE, Padley RJ (1996) The hytrin community assessment trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 47: 159-168
22. Lepor H (1995) Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 45: 406-413
23. Lepor H, Williford WO, Barry MJ et al. (1996) The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med 335: 533-539